Skip to main content

Sars-CoV2

4
Pipeline Programs
8
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
1
0
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
1100%
+ 7 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
OctagamPhase 4
BioAegis Therapeutics
BioAegis TherapeuticsNJ - North Brunswick
1 program
1
Recombinant human plasma gelsolinPhase 21 trial
Active Trials
NCT04358406Completed64Est. Jan 2022
Design Pharmaceuticals
1 program
1
ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLSPhase 1/2
Syneos Health
Syneos HealthNC - Morrisville
1 program
1
MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcgPhase 1Vaccine1 trial
Active Trials
NCT04495933Completed216Est. Apr 2024
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Risk Prediction and Therapy Monitoring in Patients With SARS-Cov-2 Infection / COVID 19N/A1 trial
Active Trials
NCT04456075Unknown100Est. Apr 2022
Design Therapeutics
1 program
ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLSPHASE_1_21 trial
Active Trials
NCT04366323Completed26Est. Dec 2021
Vaxart
VaxartSOUTH SAN FRANCISCO, CA
1 program
VXA-CoV2-3.1PHASE_21 trial
Active Trials
NCT06672055Active Not Recruiting10,400Est. Nov 2026
Octapharma
OctapharmaAustria - Vienna
1 program
OctagamPHASE_41 trial
Active Trials
NCT04411667Completed34Est. Jun 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
OctapharmaOctagam
VaxartVXA-CoV2-3.1
BioAegis TherapeuticsRecombinant human plasma gelsolin
Design TherapeuticsALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS
Syneos HealthMF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg
Heidelberg PharmaRisk Prediction and Therapy Monitoring in Patients With SARS-Cov-2 Infection / COVID 19

Clinical Trials (6)

Total enrollment: 10,840 patients across 6 trials

NCT04411667OctapharmaOctagam

Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19

Start: Apr 2020Est. completion: Jun 202034 patients
Phase 4Completed
NCT06672055VaxartVXA-CoV2-3.1

A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

Start: Oct 2024Est. completion: Nov 202610,400 patients
Phase 2Active Not Recruiting
NCT04358406BioAegis TherapeuticsRecombinant human plasma gelsolin

Rhu-pGSN for Severe Covid-19 Pneumonia

Start: Jul 2020Est. completion: Jan 202264 patients
Phase 2Completed
NCT04366323Design TherapeuticsALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS

Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19

Start: Apr 2020Est. completion: Dec 202126 patients
Phase 1/2Completed
NCT04495933Syneos HealthMF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg

A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults

Start: Jul 2020Est. completion: Apr 2024216 patients
Phase 1Completed
NCT04456075Heidelberg PharmaRisk Prediction and Therapy Monitoring in Patients With SARS-Cov-2 Infection / COVID 19

Risk Prediction and Therapy Monitoring in Patients With SARS-Cov-2 Infection / COVID 19

Start: Apr 2020Est. completion: Apr 2022100 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.